Maternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsia
Kirsten R. Palmer*, Tu'uhevaha J. Kaitu'u-Lino, Ping Cannon, Laura Tuohey, Manarangi S. De Silva, Manuel Varas-Godoy, Stephanie Acuña, José Galaz, Stephen Tong, Sebastián E. Illanes
Claustro Doctorado en Biomedicina
Objective: sFLT-1 e15a is a recently described sFlt-1 variant that is placental and primate specific. As such, it may have potential as a biomarker. Using a newly developed ELISA, we measured maternal plasma sFLT-1 e15a levels in women with fetal growth restriction and pre-eclampsia. Method: We performed a nested case-control study where we measured total sFLT-1 and sFLT-1 e15a plasma protein concentrations. Samples, selected from a prospective cohort study, consisted of 87 healthy controls, 11 cases that developed term preeclampsia and 20 cases where there was fetal growth restriction. We also measured sFLT-1 and sFLT-1 e15a plasma concentrations in a separate cohort: 15 cases of preterm preeclampsia and 24 healthy controls. Results: The prospective case-control cohort demonstrated significantly increased sFLT-1 e15a among cases with term fetal growth restriction (p < 0.05). We also observed that total sFLT-1 (this ELISA indiscriminately detects all variants) was significantly increased in term preeclampsia (p < 0.0001), but not fetal growth restriction. The separate cohort of early-onset preeclamptics showed significantly increased sFLT-1 e15a levels (p < 0.0001). Conclusion: Plasma sFLT-1 e15a is significantly increased in early-onset preeclampsia and term fetal growth restriction. Further assessment of the benefit for sFLT-1 e15a testing in prediction or diagnosis of these disease states is warranted.
Journal of Maternal-Fetal and Neonatal Medicine
© 2016 Informa UK Limited, trading as Taylor & Francis Group.
Anti-angiogenic
sFLT-1 variant
small for gestational age
Dive into the research topics of 'Maternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsia'. Together they form a unique fingerprint.
Fetal Growth Retardation Medicine & Life Sciences 100%
Pre-Eclampsia Medicine & Life Sciences 90%
Enzyme-Linked Immunosorbent Assay Medicine & Life Sciences 25%
Primates Medicine & Life Sciences 16%
Blood Proteins Medicine & Life Sciences 16%
Case-Control Studies Medicine & Life Sciences 14%
Palmer, K. R., Kaitu'u-Lino, T. J., Cannon, P., Tuohey, L., De Silva, M. S., Varas-Godoy, M., Acuña, S., Galaz, J., Tong, S., & Illanes, S. E. (2017). Maternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 30(6), 635-639. https://doi.org/10.1080/14767058.2016.1182975
Palmer, Kirsten R. ; Kaitu'u-Lino, Tu'uhevaha J. ; Cannon, Ping ; Tuohey, Laura ; De Silva, Manarangi S. ; Varas-Godoy, Manuel ; Acuña, Stephanie ; Galaz, José ; Tong, Stephen ; Illanes, Sebastián E. / Maternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsia. In: Journal of Maternal-Fetal and Neonatal Medicine. 2017 ; Vol. 30, No. 6. pp. 635-639.
@article{89bd462c73f9458eb850eb243641827d,
title = "Maternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsia",
abstract = "Objective: sFLT-1 e15a is a recently described sFlt-1 variant that is placental and primate specific. As such, it may have potential as a biomarker. Using a newly developed ELISA, we measured maternal plasma sFLT-1 e15a levels in women with fetal growth restriction and pre-eclampsia. Method: We performed a nested case-control study where we measured total sFLT-1 and sFLT-1 e15a plasma protein concentrations. Samples, selected from a prospective cohort study, consisted of 87 healthy controls, 11 cases that developed term preeclampsia and 20 cases where there was fetal growth restriction. We also measured sFLT-1 and sFLT-1 e15a plasma concentrations in a separate cohort: 15 cases of preterm preeclampsia and 24 healthy controls. Results: The prospective case-control cohort demonstrated significantly increased sFLT-1 e15a among cases with term fetal growth restriction (p < 0.05). We also observed that total sFLT-1 (this ELISA indiscriminately detects all variants) was significantly increased in term preeclampsia (p < 0.0001), but not fetal growth restriction. The separate cohort of early-onset preeclamptics showed significantly increased sFLT-1 e15a levels (p < 0.0001). Conclusion: Plasma sFLT-1 e15a is significantly increased in early-onset preeclampsia and term fetal growth restriction. Further assessment of the benefit for sFLT-1 e15a testing in prediction or diagnosis of these disease states is warranted.",
keywords = "Anti-angiogenic, pre-eclampsia, pregnancy, sFLT-1 variant, small for gestational age, Anti-angiogenic, pre-eclampsia, pregnancy, sFLT-1 variant, Small for gestational age",
author = "Palmer, {Kirsten R.} and Kaitu{\textquoteright}u-Lino, {Tu{\textquoteright}uhevaha J.} and Ping Cannon and Laura Tuohey and {De Silva}, {Manarangi S.} and Manuel Varas-Godoy and Stephanie Acu{\~n}a and Jos{\'e} Galaz and Stephen Tong and Illanes, {Sebasti{\'a}n E.}",
note = "Publisher Copyright: {\textcopyright} 2016 Informa UK Limited, trading as Taylor & Francis Group.",
journal = "Journal of Maternal-Fetal and Neonatal Medicine",
publisher = "Informa Healthcare",
Palmer, KR, Kaitu'u-Lino, TJ, Cannon, P, Tuohey, L, De Silva, MS, Varas-Godoy, M, Acuña, S, Galaz, J, Tong, S & Illanes, SE 2017, 'Maternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsia', Journal of Maternal-Fetal and Neonatal Medicine, vol. 30, no. 6, pp. 635-639. https://doi.org/10.1080/14767058.2016.1182975
Maternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsia. / Palmer, Kirsten R.; Kaitu'u-Lino, Tu'uhevaha J.; Cannon, Ping; Tuohey, Laura; De Silva, Manarangi S.; Varas-Godoy, Manuel; Acuña, Stephanie; Galaz, José; Tong, Stephen; Illanes, Sebastián E.
In: Journal of Maternal-Fetal and Neonatal Medicine, Vol. 30, No. 6, 19.03.2017, p. 635-639.
T1 - Maternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsia
AU - Palmer, Kirsten R.
AU - Kaitu'u-Lino, Tu'uhevaha J.
AU - Cannon, Ping
AU - Tuohey, Laura
AU - De Silva, Manarangi S.
AU - Varas-Godoy, Manuel
AU - Acuña, Stephanie
AU - Galaz, José
AU - Tong, Stephen
AU - Illanes, Sebastián E.
N1 - Publisher Copyright: © 2016 Informa UK Limited, trading as Taylor & Francis Group.
N2 - Objective: sFLT-1 e15a is a recently described sFlt-1 variant that is placental and primate specific. As such, it may have potential as a biomarker. Using a newly developed ELISA, we measured maternal plasma sFLT-1 e15a levels in women with fetal growth restriction and pre-eclampsia. Method: We performed a nested case-control study where we measured total sFLT-1 and sFLT-1 e15a plasma protein concentrations. Samples, selected from a prospective cohort study, consisted of 87 healthy controls, 11 cases that developed term preeclampsia and 20 cases where there was fetal growth restriction. We also measured sFLT-1 and sFLT-1 e15a plasma concentrations in a separate cohort: 15 cases of preterm preeclampsia and 24 healthy controls. Results: The prospective case-control cohort demonstrated significantly increased sFLT-1 e15a among cases with term fetal growth restriction (p < 0.05). We also observed that total sFLT-1 (this ELISA indiscriminately detects all variants) was significantly increased in term preeclampsia (p < 0.0001), but not fetal growth restriction. The separate cohort of early-onset preeclamptics showed significantly increased sFLT-1 e15a levels (p < 0.0001). Conclusion: Plasma sFLT-1 e15a is significantly increased in early-onset preeclampsia and term fetal growth restriction. Further assessment of the benefit for sFLT-1 e15a testing in prediction or diagnosis of these disease states is warranted.
AB - Objective: sFLT-1 e15a is a recently described sFlt-1 variant that is placental and primate specific. As such, it may have potential as a biomarker. Using a newly developed ELISA, we measured maternal plasma sFLT-1 e15a levels in women with fetal growth restriction and pre-eclampsia. Method: We performed a nested case-control study where we measured total sFLT-1 and sFLT-1 e15a plasma protein concentrations. Samples, selected from a prospective cohort study, consisted of 87 healthy controls, 11 cases that developed term preeclampsia and 20 cases where there was fetal growth restriction. We also measured sFLT-1 and sFLT-1 e15a plasma concentrations in a separate cohort: 15 cases of preterm preeclampsia and 24 healthy controls. Results: The prospective case-control cohort demonstrated significantly increased sFLT-1 e15a among cases with term fetal growth restriction (p < 0.05). We also observed that total sFLT-1 (this ELISA indiscriminately detects all variants) was significantly increased in term preeclampsia (p < 0.0001), but not fetal growth restriction. The separate cohort of early-onset preeclamptics showed significantly increased sFLT-1 e15a levels (p < 0.0001). Conclusion: Plasma sFLT-1 e15a is significantly increased in early-onset preeclampsia and term fetal growth restriction. Further assessment of the benefit for sFLT-1 e15a testing in prediction or diagnosis of these disease states is warranted.
KW - Anti-angiogenic
KW - pre-eclampsia
KW - pregnancy
KW - sFLT-1 variant
KW - small for gestational age
JO - Journal of Maternal-Fetal and Neonatal Medicine
JF - Journal of Maternal-Fetal and Neonatal Medicine
Palmer KR, Kaitu'u-Lino TJ, Cannon P, Tuohey L, De Silva MS, Varas-Godoy M et al. Maternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine. 2017 Mar 19;30(6):635-639. https://doi.org/10.1080/14767058.2016.1182975